

Hellenic Journal of Nuclear Medicine

Volume 25 • Number 1 • January-April 2022

Indexed/abstracted by: MEDLINE, Science Citation Index Expanded, Journal Citation Reports/Science Edition, EMBASE, Thomson-Reuters and Scopus Info and Index Copernicus. Listed by the International Centre for Scientific Research

The first hellenic journal of nuclear medicine

Impact factor: 1.102



Editorial: Medical historians and historians of Medicine: Time for a truce. S. Retsas 2

Original Articles: The relationship between Her2 expression and ¹⁸F-FDG in gastric carcinoma. A. Ozen, G. Tatar 5

- Role of ¹⁸F-DCFPyL PET/CT in patients with suspected prostate cancer. T. Zhang, S. Yang et al. 11

- ¹⁸F-FDG PET/CT value in the detection of seminoma and correlation with CT and tumor marker levels-up to 8 years of follow-up. J. Petrović, S. Beatović et al. 19

-Development of hypothyroidism over 13 years of follow-up of patients with hyperthyroidism after radioiodine therapy. J. F. Li, L. J. Xie et al. 26

- Clinical value of the threshold derived from bone single-photon emission computed tomography/ computed tomography in differentiating sternoclavicular arthritis. T. Tsuchitani, K. Kitajima et al. 32

- Correlation among maximum standardized ¹⁸F-FDG uptake and pathological differentiation, tumor size, and Ki67 in patients with moderately and poorly differentiated intrahepatic cholangiocarcinoma. Y. Zhang, B. Li et al. 38

- SPECT analysis and language profile in Greek speaking patients with subtypes of frontotemporal dementia. D. Mamouli, S. Stavrakaki et al. 43

- Characterization of bone metastases detected on ⁶⁸Ga-PSMA PET/CT in newly diagnosed prostate cancer. H. Öner, F. Yılmaz 57

- Metabolic tumor volume derived from ¹⁸F-FDG PET/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients. C. Ding, X. Mao et al. 63

- An image-based notion for therapeutic planar organ activity dosimetry in a developing country: Masterdose software. B. Van Wyk, F. Hasford et al. 71

Review Articles: Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET/CT imaging. E. Pasini, E. Panagiotidis et al. 83


- Diagnostic accuracy of ¹⁸F-PSMA-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis. X. Liu, Qi. Wang et al. 88

Case Report: A rare involvement of diffuse large B-cell lymphoma: Peritoneal lymphomatosis with a peritoneal super-scan appearance on ¹⁸F-FDG PET/CT. F. Yılmaz, H. Öner. 103

Images: ¹⁸F-FDG PET/CT imaging of pseudomyogenic hemangioperithelioma presenting as multiple nodules with right ventricle and pancreas involvement. L. Xiao, L. Zhang et al. 106

- Relapsing polychondritis revealed by ¹⁸F-FDG and AI ¹⁸F-NOTA-FAPI-04 PET/CT. M. Ni, Q. Xie et al. 108

- A case of ⁶⁸Ga-PSMA PET early dynamic image revealing occult recurrent lesion in the posterior wall of the urinary bladder. L. Xiao, H. Wang et al. 111



2020 The 2nd production unit in Lakkoma, Chalkidiki becomes fully operational and covers the entire region of Northern Greece and the Balkan countries.

2018 The installation of the production equipment in the 2nd production unit is completed.

2017 The construction of a 2nd production unit in Lakkoma, Chalkidiki commences with an equivalent capacity yet newer technology than that in Lavrio.

2011 The production capacity of the facilities in Lavrio is doubled, with a major investment in human resources and state-of-the-art equipment.

2000 The Company's vision is decided and launched: The construction and operation of the first production unit for PET radiopharmaceuticals in Greece.

1992 The company BIODOSMOS S.A. is established

BIOKOSMOS S.A.



ATTICA
Area Panomos, 19500
Lavrio Attiki - Greece



NORTHERN GREECE
Lakoma Industrial Area
Halkidiki, 630 80



Phone center:
Tel: +30 22920 63900
Fax: +30 22920 69235

www.biokosmos.eu